Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2012 1
2013 11
2014 100
2015 104
2016 70
2017 79
2018 92
2019 103
2020 106
2021 107
2022 61
Text availability
Article attribute
Article type
Publication date

Search Results

693 results
Results by year
Filters applied: . Clear all
Page 1
Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group.
Miller TP, Getz KD, Li Y, Demissei BG, Adamson PC, Alonzo TA, Burrows E, Cao L, Castellino SM, Daves MH, Fisher BT, Gerbing R, Grundmeier RW, Krause EM, Lee J, Lupo PJ, Rabin KR, Ramos M, Scheurer ME, Wilkes JJ, Winestone LE, Hawkins DS, Gramatges MM, Aplenc R. Miller TP, et al. Lancet Haematol. 2022 Sep;9(9):e678-e688. doi: 10.1016/S2352-3026(22)00168-5. Epub 2022 Jul 20. Lancet Haematol. 2022. PMID: 35870472
Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19.
Diorio C, Shraim R, Myers R, Behrens EM, Canna S, Bassiri H, Aplenc R, Burudpakdee C, Chen F, DiNofia AM, Gill S, Gonzalez V, Lambert MP, Leahy AB, Levine BL, Lindell RB, Maude SL, Melenhorst JJ, Newman H, Perazzelli J, Seif AE, Lacey SF, June CH, Barrett DM, Grupp SA, Teachey DT. Diorio C, et al. Clin Cancer Res. 2022 Sep 1;28(17):3804-3813. doi: 10.1158/1078-0432.CCR-22-0822. Clin Cancer Res. 2022. PMID: 35705524
Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma.
Budde A, Baust K, Weinhold L, Bernstein M, Bielack S, Dhooge C, Hjorth L, Janeway KA, Jenney M, Krailo MD, Marina N, Nagarajan R, Smeland S, Sydes MR, De Vos P, Whelan J, Wiener A, Calaminus G, Schmid M. Budde A, et al. Eur J Cancer. 2022 Jul;170:209-235. doi: 10.1016/j.ejca.2022.03.018. Epub 2022 Jun 8. Eur J Cancer. 2022. PMID: 35689897 Free PMC article.
A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.
Gbadamosi MO, Shastri VM, Elsayed AH, Ries R, Olabige O, Nguyen NHK, De Jesus A, Wang YC, Dang A, Hirsch BA, Alonzo TA, Gamis A, Meshinchi S, Lamba JK. Gbadamosi MO, et al. Leukemia. 2022 Aug;36(8):2022-2031. doi: 10.1038/s41375-022-01622-0. Epub 2022 Jun 10. Leukemia. 2022. PMID: 35688939
Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533.
Madanat-Harjuoja LM, Renfro LA, Klega K, Tornwall B, Thorner AR, Nag A, Dix D, Dome JS, Diller LR, Fernandez CV, Mullen EA, Crompton BD. Madanat-Harjuoja LM, et al. J Clin Oncol. 2022 Sep 10;40(26):3047-3056. doi: 10.1200/JCO.22.00098. Epub 2022 May 17. J Clin Oncol. 2022. PMID: 35580298 Free PMC article. Clinical Trial.
693 results